1. Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers 
Pasquale Rescigno, David Lorente, David Dolling, Roberta Ferraldeschi, Daniel Nava Rodrigues, Ruth Riisnaes, Susana Miranda, Diletta Bianchini, Zafeiris Zafeiriou, Spyridon Sideris, Ana Ferreira, Ines Figueiredo, Semini Sumanasuriya, Joaquin Mateo, Raquel Perez-Lopez, Adam Sharp, Nina Tunariu, Johann S. de Bono 
European Urology Oncology 
Volume 1, Issue 1, Pages (May 2018)
DOI: /j.euo
Copyright © 2018 European Association of Urology Terms and Conditions

2. Fig. 1
Kaplan-Meier curves for (A) median overall survival (OS) and (B) median progression-free survival (PFS) from the start of docetaxel chemotherapy for patients with PTEN loss and those with PTEN-positive tumors. CI=confidence interval; DTX=docetaxel.
European Urology Oncology 2018 1, 71-77DOI: ( /j.euo )
Copyright © 2018 European Association of Urology Terms and Conditions

3. Fig. 2
Waterfall plot of prostate-specific antigen (PSA) change for patients with PTEN loss and those still PTEN-positive. The bar indicates a 30% decline in PSA from baseline.
European Urology Oncology 2018 1, 71-77DOI: ( /j.euo )
Copyright © 2018 European Association of Urology Terms and Conditions